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The efficacy, safety, and pharmacokinetics of intramuscular
and oral phenyramidol in patients with low back pain in an
emergency department
Hakan ERGÜN1, Onur POLAT2, N. Arda DEMİRKAN2, Müge GÜNALP2, Serdar GÜRLER2

Aim: To compare the efficacy, safety, and pharmacokinetics of oral and intramuscular (i.m.) phenyramidol in patients
with low back pain.
Materials and methods: Consecutive patients with low back pain were recruited and randomized (5:3) to treatment
with either 800 mg oral or i.m. phenyramidol. Pain was assessed by visual analogue scale every 30 min for 2 h. Blood
samples were drawn at baseline and every 15 min for 2 h. A 5-point verbal global evaluation scale was performed by both
patients and physicians. In addition, the need for rescue analgesics after 2 h was noted. After the acute phase, patients
were re-randomized (5:3) to receive either a placebo tablet or a 400 mg phenyramidol tablet 3 times a day for 7 days.
Efficacy of the long term treatment was measured by the evaluation of both patients and physicians (with a 5-point verbal
global evaluation scale) and by the daily amount of naproxen sodium consumed as the rescue analgesic drug.
Results: Seventy-two patients (45F/27M) had a marked improvement in pain scores, with no significant difference
between the groups. Sixty-one (39F/22M) patients completed the second phase, in which no difference in any parameter
was noted. Seven of 38 patients in phenyramidol group had elevated liver enzymes at the end of the chronic treatment
phase which normalized after 1 week. Only the Tmax pharmacokinetic parameter (Cmax, Tmax, t½, and AUC) was significantly
but slightly different between the groups.
Conclusion: Liver enzymes should be monitored in patients taking repeated dose of phenyramidol and should not be
used in combination with analgesics bearing hepatotoxicity potential, such as paracetamol.
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Acil servise bel ağrısı şikayeti ile başvuran hastalarda oral ve i.m. feniramidolün
etkililiği, güvenliliği ve farmakokinetik özellikleri
Amaç: Bel ağrısı olan hastalarda oral ve kas içine (i.m.) feniramidol uygulamasının etkililiği, güvenliliği ve farmakokinetik
parametrelerinin karşılaştırılması.
Yöntem ve gereç: Bel ağrısı nedeniyle başvuran ardışık hastalar, 800 mg oral veya i.m. feniramidol tedavisi için randomize
edilerek (5:3) çalışmaya dahil edildi. Ağrı, iki saat boyunca her 30 dakikada bir görsel analog ölçek ile değerlendirildi. Kan
örnekleri ilaç uygulamadan hemen önce ve iki saat boyunca her onbeş dakikada bir alındı. Etkililik, hasta ve doktorun
değerlendirmesi (beş noktalı genel değerlendirme ölçeği ile) ve ilave olarak iki saat sonunda ağrı kesici gereksinimi ile
tespit edildi. Akut fazın ardından hastalar 7 gün boyunca plasebo veya 400 mg feniramidol (günde 3 kez) almak üzere
yeniden randomize edildi (5:3). Kronik tedavinin etkililiği hasta ve doktorun değerlendirmesi (beş noktalı genel
değerlendirme ölçeği ile) ve kurtarıcı ilaç olarak kullanılan naproksen sodyumun günlük kullanım miktarı ile
değerlendirildi.
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Bulgular: Yetmişiki (45K/27E) hastanın ağrısı gruplar arasında fark olmaksızın belirgin bir biçimde azaldı. Altmışbir
(39K/22E) hasta çalışmanın ikinci bölümünü (değerlendirilen parametrelerde gruplar arasında fark olmaksızın)
tamamladı. Feniramidol tedavi grubunda olan 38 hastanın yedisinde karaciğer enzimlerinde bir haftalık takip ardından
normal düzeye dönen artış tespit edildi. Farmakokinetik parametrelerden (Cmax, Tmax, t½ and AUC) yalnız Tmax süresinde
istatistiksel olarak anlamlı ancak küçük fark belirlendi.
Sonuç: Uzun süreli feniramidol kullanan hastaların karaciğer enzimleri izlenmeli ve parasetamol gibi karaciğer toksisitesi
olan ağrı kesiciler ile birlikte uygulanmamalıdır.
Anahtar sözcükler: Feniramidol, bel ağrısı, farmakokinetik, acil servis

Introduction

Material and methods

Low back pain (LBP) is a very common medical
condition, occurring in up to 90% of all adults at least
once in their lives. Although most cases resolve
spontaneously within a few days to weeks without
sequelae, loss of productivity in the workplace can be
significant (1). Many patients with acute low back
pain present to the emergency department (ED) for
care. Many options and routes for treatment with
analgesics and/or skeletal muscle relaxant agents exist
(2,3).

This double-blind, randomized study was
conducted in the ED of our tertiary-care university
hospital. The study was performed in accordance with
the Declaration of Helsinki and with local regulations
on the use of therapeutic agents in patients. The
protocol was approved by the local ethics committee
of Ankara University, Faculty of Medicine, and
conducted according to the International Conference
on Harmonization-Good Clinical Practice (ICHGCP) guidelines. All patients provided written
informed consent before enrolling in the study.

Phenyramidol is an aminopyridine derivative with
skeletal muscle relaxant properties. It was introduced
as an oral agent into clinical practice in 1960 and is
still available as a tablet for oral use and as an ampoule
for intramuscular (i.m.) use (4). Although it has been
in use for over 45 years, limited data exist about its
efficacy and safety. To date, only 3 comparative
clinical trials measuring its efficacy have been
performed (5-7). Other reports have found
phenyramidol to be beneficial in premenstrual
syndrome and various musculoskeletal conditions (89). Koksal et al. reported a patient who had elevated
liver enzymes during treatment with phenyramidol,
probably an adverse-effect of the medication (10).
In the 2 phases of this study, we investigated the
efficacy and safety of phenyramidol in patients
presenting to the ED with LBP. In the first phase, oral
and i.m. forms of phenyramidol were compared
during the first 2 hours of the patient’s ED stay. In the
second phase, the efficacy and safety of oral
phenyramidol were compared with placebo in the
same patients after they were discharged home from
the ED. Finally, pharmacokinetic parameters (Cmax,
Tmax, t½ and AUC) after oral and i.m. administration
were measured and compared.
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Subjects and inclusion criteria
Adult patients, 18-55 years old, with a primary
complaint of LBP and admitting to the ED of our
tertiary university hospital were evaluated for
inclusion in the study. Blood was taken from the
patients for the measurement of AST, ALT, BUN, and
creatinine levels.
Exclusion criteria
Patients were excluded if they had abnormal levels
of AST, ALT, BUN, or creatinine, pre-treatment with
any skeletal muscle relaxants or analgesic drug in the
previous 12 h, hypersensitivity or other
contraindications to NSAIDs or skeletal muscle
relaxants, any pre-existing disease or conditions, or
any concomitant therapy that may interfere with the
mode of action of the study drugs. Patients with any
red flags, which might indicate serious spinal, sciatic
nerve, pelvic or abdominal pathology, were also
excluded, as were those who we thought would not
comply with the study protocol. Breast-feeding
women and women with proven or assumed
pregnancy were also excluded from the study.
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Study design
Patients and assessors were blinded to treatment
as follows. All tablets and i.m. forms of phenyramidol
and placebo were in original packaging. Only the
serial number on each package differed from one
another, and the contents were known only by one of
the authors (H.E.) and kept in a big package, which
was marked as “A” or “B” to preserve the blindness of
investigators to the study groups. A randomization
scheme was prepared and consecutive patients
received their treatment according to protocol as “A”
or “B” for both phases of the study. In the first phase,
the efficacy, safety, and pharmacokinetics of oral and
i.m. 800 mg phenyramidol were evaluated and
compared during a 2-h period in the ED. In the
second phase, the efficacy and safety of phenyramidol
were compared with placebo over a 1-week period.
Acute phase
After an initial screening (122 patients were
screened and 59% of them were enrolled), 45 patients
were randomized (5:3) to receive oral (2 × 400 mg
sugar-coated tablets) and 27 patients to receive i.m.
(800 mg ampoule) phenyramidol. To preserve the
blindness, the i.m. treatment group received identical
placebo tablets and the oral treatment group the same
amount (3 mL) of i.m. 0.9% NaCl. Both tablets and
ampoules were donated by the Dr. F. Frik
Pharmaceutical Company, the only producer of
phenyramidol in Turkey.
Pain intensity was assessed by patients using a
visual analogue scale (a 100 mm-long line, marked
with numbers from 0 to 10) before and every 30 min
after treatment for 2 h. At the same time, blood
samples were drawn into K3 EDTA tubes just before
ingestion or injection of phenyramidol and every 15
min for 2 h. After the 2-h observation period, patients
were asked if they need any additional analgesics. At
the 2-h point, patients and physicians reported pain
relief as not effective, slightly effective, mildly
effective, effective, or very effective, on a 5-point
global evaluation scale. Blood samples were
immediately centrifuged and plasma was stored at 80 °C in the dark. For analysis, samples were shipped
in packages in dry ice to India and stored again at -80
°C in the dark until analyzed. The pharmacokinetic
parameters, time to reach maximum concentration

(tmax), maximum concentration of phenyramidol
(Cmax), area under the curve (AUC) elimination halflife, were calculated after fitting to the data.
Chronic phase
After the acute phase, same patients were rerandomized to receive placebo or 400 mg of
phenyramidol 3 times a day for 7 days. All patients
also received 20 tablets (275 mg/tablet) of naproxen
sodium as rescue medication. They were instructed
to take this rescue medication in case their pain was
not relieved by their study medication and not to take
more than 4 tablets a day. The patients were also told
that they could ask for and receive another box of
rescue medicine in case they finished the 20-tablet
box. Patients kept a diary to record medications they
had taken and the time of ingestion. Efficacy of long
term treatment was measured by patients’ and
physicians’ global evaluation score (5 point verbal
scale) and daily consumption of rescue analgesia
(naproxen sodium) during the 7-day period. On day
7, a blood sample was drawn 8 h after the last dose of
phenyramidol for the evaluation of the steady state
concentration (Css) of phenyramidol and levels of
hepatic enzymes.
Analytical assay for plasma phenyramidol levels
Phenyramidol analysis was performed using liquid
chromatography and mass detection by the Drug
Monitoring Research Institute PVT LT Rabale, Navi
Mumbai, India. Limits of detection were between 50
and 3.474 ng/mL. Biochemical analysis was as follows:
each plasma sample (0.5 mL) was mixed with 20 μL
metoprolol (1040 μg/mL) as an internal standard,
buffered with 200 μL of 5 mM dipotassium hydrogen
phosphate and extracted with 4 mL of methyl tertiary
butyl ether (MTBE). After centrifuging for 2 min, 3
mL of the organic layer was transferred into an
evaporating tube and evaporated under a nitrogen
stream at 45 °C. The residue was reconstituted with
1000 μL of the mobile phase, and an aliquot of 2 μL
was directly injected onto the HPLC column.
The HPLC system consisted of a Hypurity C18 (50
× 4.6 mm, 5 μ) column, MRM Positive detector,
acetonitrile + 2 mM ammonium acetate [pH: 3.5]
(v/v: 90:10) mobile phase, 0.90 mL/min flow rate with
3-way splitting. Retention times for phenyramidol and
metoprolol were 0.65 ± 1 min and 1.5 ± 1 min,
respectively, with a run time of 3 min.
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Sample Size Estimation/Power Analysis
Sample size was estimated using the chronic phase
primary parameter “average daily analgesic
consumption”. A decrease of daily 0.5 tablet
consumption was chosen by the authors as clinically
significant. This is an effect size of 0.5 with a SD ± 0.5,
5/3 randomization ratio, and a power of 95%.
According to this calculation using the NCSS/PASS
2002 program, 57 (21/36) subjects were needed to
detect a 0.5 tablet difference between the groups. We
have estimated a 20% of drop-out rate after the initial
acute phase. Therefore, the above calculated sample
size was multiplied with 1.2 and corrected to be
dividable to 8 (total 72 patients). The power analysis
for the primary endpoint “VAS score” in the acute
phase were calculated for a 10 mm ± 10 SD and 5/3
randomization ratio and found 98%.
Statistical Analysis
All data were presented as mean (±SEM), median,
or percent. Groups were compared using unpaired
Student’s t test, Mann-Whitney U test, chi-square test,
or ANOVA for repeated measures as appropriate.
Results
Acute phase
Seventy-two patients (45F/27M) completed the
acute phase of the study. The i.m. (n = 27) and oral (n
= 45) treatment groups were not significantly different

in terms of gender (59% vs. 64% female, respectively)
or mean age (36 ± 10 years vs. 38 ± 10 years,
respectively). Three (11%) patients in the i.m.
treatment group and 5 (11%) in the oral treatment
group (n.s.) reported headache, emesis, dry mouth, or
dizziness, which were all mild to moderate and did
not require any treatment. Regarding the efficacy of
the treatment, pain intensity decreased in both
groups, with no significant difference between the
groups at any time point (Figure 1). The f (time ×
group interaction) and P values were found 0.657 and
0.624, respectively. Rescue analgesics were needed
after the 2-h observation period in 4 (15%) patients
in the i.m. and 4 (9%) patients in the oral treatment
group (n.s.). The median global evaluation scores of
both patients and physicians were ‘mildly effective’ for
both treatment groups.
Blood samples for pharmacokinetic evaluation
were measured from 23 and 22 patients in the i.m. and
oral treatment groups, respectively. Only the Tmax
value significantly but slightly differed between the
groups. The remaining pharmacokinetic parameters
(Cmax, t½, and AUC) were not significantly different
between the administration routes. Five patients in
each group demonstrated a second peak, which was
more distinctive in the oral treatment group (Figure
2). Phenyramidol Css levels measured 8 h after the last
dose of phenyramidol were mostly under the
detection limit (only 5 out of 21 patients had a
measurable plasma level of phenyramidol; mean of
these 5 patients: 336 ± 99 ng/mL).
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Figure 1. Pain intensity, as measured with a visual analogue scale
(0-100 mm) after intramuscular or oral administration
of 800 mg phenyramidol in patients with nonspecific
low back pain, reported as mean ± SEM. Time 0
indicates pain intensity at baseline, just before
administration of the study agent.
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Figure 2. Time course of plasma phenyramidol concentrations
in patients with nonspecific low back pain after
receiving a single 800 mg dose of phenyramidol by
intramuscular or oral route.
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Chronic phase
Although all patients agreed to continue in the
second phase of the study, only 61 (39F/22M) patients
completed this phase. Two from the placebo group
and 4 from the oral treatment group out of 11 patients
did not show up and 2 from the placebo and 3 from
the oral treatment group had protocol violations
(missing doses in 4, and ingestion of disallowed
medications in 1). Patients in the phenyramidol (n =
38) and placebo (n = 23) groups were not significantly
different in terms of gender (68% and 56% female,
respectively) or mean age (37±10 years and 38±11
years, respectively). Rescue analgesics were used less
than 1 tablet/day and did not differ significantly
between groups. The median patient and physician
global evaluation scores were ‘mildly effective’ for
both treatment groups (n.s.). Although not
significantly different, more adverse effects occurred
in the treatment group [32%, emesis, weakness,
abdominal discomfort (n = 2), dizziness (n = 3), and
elevated liver enzymes (n = 7)] compared to the
placebo group (17%, headache, dry mouth, itching,
and loss of sense of taste), but none of the adverse
effects required treatment. At the end of the 1-week
treatment period, 7 out of 38 patients in the
phenyramidol treatment group and none in the
placebo group had elevated liver enzymes. These 7
patients were checked again 1 week later, and AST and
ALT levels returned to normal values in all patients.

In clinical practice, if the initial treatment for a
condition is successful, many physicians continue the
same treatment during the patient’s outpatient course.
For this reason, we re-randomized the ED patients to
receive oral phenyramidol or placebo for an
additional week to investigate its efficacy and safety
over a longer period of time. In contrast to our
expectations, no significant differences between the
groups were found. However, it should be noted that
the present study was limited to a specific patient
population, those with low back pain in the ED who
had no serious spinal pathology. In our study we have
evaluated the daily analgesic consumption as the
primary parameter for the second phase.
Additionally, global evaluation of both patients and
physicians were involved as the second efficacy
parameter. It may be suggested that there are other
parameters, such as evaluating the muscle spasm or
physical function measures as efficacy parameters.
However, due to our clinical setting it was not possible
to evaluate all the patients by a single physician.

Discussion

Even though the adverse effects were not serious
and did not require treatment, a significant
proportion (18%) of patients treated with
phenyramidol for 1 week developed elevations in liver
enzymes. This finding is important when considering
prescribing phenyramidol to patients who have
concomitant potentially hepatotoxic treatments or
previous hepatic diseases. Fortunately in this study,
high liver enzyme levels in all 7 patients returned to
normal within 1 week after stopping the medication.

The aim of this study was to evaluate the efficacy,
safety, and pharmacokinetics of phenyramidol when
given via the oral or i.m. route. Both forms have
almost the same pharmacokinetic characteristics,
which agree with similar efficacy and safety of both
forms of the drug in this patient population. This
clinical trial is the first to compare the efficacy and
safety of phenyramidol administered via 2 different
routes, and we found no difference between i.m. and
oral phenyramidol when given to patients with nonspecific LBP in the ED. The analgesics and muscle
relaxants used in many LBP patients in the ED should
be cost-effective and minimally invasive. Based on the
efficacy and pharmacokinetics data from this study,
oral administration of phenyramidol would be a
better choice if no contraindications exist.

It was remarkable that the first case of elevated
liver enzymes that developed during treatment with
oral phenyramidol, a product that has been on the
market for over 40 years, was reported in 2003 (10). In
that case, the 70-year-old patient’s liver enzymes
returned to normal after discontinuation of
phenyramidol, as in our patients. This relatively new
finding of elevated liver enzymes after phenyramidol
use may be explained in several ways: compliance
with a prescribed regimen of analgesics may be poor
in situations that often improve over time,
phenyramidol may be used in many individuals with
pain but who have no underlying liver disease, and
the mild, asymptomatic elevations in liver enzymes
associated with phenyramidol use resolve without
complications when the patient stops taking the drug.
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In conclusion, oral and i.m. phenyramidol did not
differ significantly in their pain-relieving effects in
low back pain patients during their initial 2-h
treatment in the ED. After 1 week of outpatient
therapy with phenyramidol, a significant proportion
of patients developed asymptomatic elevations in liver

enzymes, which resolved with discontinuation of the
drug. Surveys regarding the adverse effects of
phenyramidol should be performed in a variety of
commonly encountered patient settings to define its
patient safety profile.
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